Karine Pozo

At Immatics, Dr. Karine Pozo leads strategic planning and execution of clinical and research programs in PRAME-directed TCR T-cell therapies. Immatics is a clinical-stage biotechnology company and the global leader in the precision targeting of PRAME. PRAME is a target expressed in more than 50 cancers and Immatics has the broadest PRAME franchise with the most PRAME indications and modalities. Karine coordinates cross-functional teams to advance TCR T-cell therapy initiatives through clinical development, supporting Immatics’ mission to make a meaningful impact on the lives of patients with cancer. Karine holds a Ph.D. in Molecular Neurosciences from the University of London.